KPIs & Operating Metrics(New)
Biopharma Testing VolumeBreakdown Of AssetsClinical VolumeContractual ObligationsCost Of RevenueCost Of Revenue By SegmentDeferred RevenueEmployee StatisticsGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome Before Provision For Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX BreakdownProperty And Equipment, NetRevenueRevenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Guardant Health (GH) Cost Of Revenue (2025)

Guardant Health's Cost of Revenue history spans 9 years, with the latest figure at -$351.3 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 330.0% to -$351.3 million in Q4 2025 year-over-year; TTM through Sep 2025 was $504.0 million, a 432.58% increase, with the full-year FY2024 number at $364.9 million, up 337.57% from a year prior.
  • Cost of Revenue hit -$351.3 million in Q4 2025 for Guardant Health, down from $127.4 million in the prior quarter.
  • Over the last five years, Cost of Revenue for GH hit a ceiling of $152.7 million in Q4 2024 and a floor of -$351.3 million in Q4 2025.
  • Historically, Cost of Revenue has averaged $47.8 million across 5 years, with a median of $73.0 million in 2022.
  • Biggest five-year swings in Cost of Revenue: soared 215.09% in 2024 and later plummeted 330.0% in 2025.
  • Tracing GH's Cost of Revenue over 5 years: stood at $59.6 million in 2021, then surged by 36.62% to $81.4 million in 2022, then tumbled by 262.98% to -$132.7 million in 2023, then soared by 215.09% to $152.7 million in 2024, then plummeted by 330.0% to -$351.3 million in 2025.
  • Business Quant data shows Cost of Revenue for GH at -$351.3 million in Q4 2025, $127.4 million in Q3 2025, and $119.6 million in Q2 2025.